INTRODUCTION
One class of antiprotozoan chemotherapeutics exploits the fact that most if not all protozoan parasites are deficient in the de novo synthesis of purine nucleotides (Wang 1984) . These organisms rely primarily on the salvage of exogenous hypoxanthine from their host which the parasites convert to IMP via the enzyme HGXPRTase, itself an attractive drug target (Somoza et al. 1996) . IMP is then converted to XMP by IMPDH ( Fig. 1 ) which is the ratelimiting enzyme in guanine nucleotide synthesis (Verham et al. 1987) . Inhibition of protozoan IMPDH with high specificity over the host enzyme is thus expected to arrest protozoan growth with minimal side effects for the host.
Tritrichomonas foetus is an anaerobic protozoan parasite that infects the urogenital tract of cows causing bovine trichomoniasis which can result in sterility and abortion (Fitzgerald 1986; Speer and White 1991) . As with most parasitic infections, there is currently no effective treatment for tritrichomonal infection. Like other protozoa, T. foetus relies on host-derived IMP for the synthesis of purine nucleotides (Wang et al. 1983) as demonstrated by the fact that in vitro growth of T. foetus is arrested by mycophenolic acid (MPA), which is a potent inhibitor of mammalian and bacterial IMPDHs (Carter et al. 1969; Franklin and Cooke 1969) .
Furthermore, this inhibition in T. foetus could be reversed by supplementing the growth medium with guanine or guanosine .
A single-copy gene for T. foetus IMPDH encodes a protein of 503 amino acids (Beck et al. 1994 ) that shares about 30 to 35% amino-acid sequence homology with known bacterial (Gilbert et al. 1979) , parasite (Wilson et al. 1991 (Wilson et al. , 1994 , and mammalian (Collart and Huberman 1988; Natsumeda et al. 1990; Tiedeman and Smith 1991) forms of the enzyme, including the two human isoforms (Carr et al. 1993) . Of the four protozoan IMPDH sequences determined to date, T. foetus IMPDH is clearly least similar to mammalian IMPDHs (Table 1) , increasing chances that one can identify an inhibitor that specifically acts on this enzyme vs the mammalian variants.
IMPDHs from all of these sources are homotetramers of about 55-kDa subunits that share a similar mechanism of catalysis. Most other known nicotinamide adenine dinucleotide (NAD)-dependent dehydrogenases undergo a conformational change following cofactor binding, thereby promoting substrate binding and catalysis (Cantor and Schimmel 1980) . In contrast, IMPDHs from all species studied to date operate via an ordered bi-bi kinetic mechanism where IMP binds before NAD and NADH is released before XMP (Verham et al. 1987) , although some doubts have recently been raised for the case of the human type II enzyme (Wang and Hedstrom 1997) . Interestingly, the mammalian enzymes require K + for catalysis while the T. foetus enzyme does not (Verham et al. 1987) .
Dehalogenation of IMP derivatives by human IMPDH in the absence of NAD indicates that the reaction mechanism proceeds via nucleophilic attack by either an OH − from water or some other nucleophile, most likely a cysteine, at the C2-position of IMP . Protection of the catalytic cysteine with 6-chloro-IMP against modification by iodoacetamide and labeling of the enzyme with radiolabeled IMP both confirmed that Cys-331 in the human enzyme and Cys-319 in the parasite enzyme perform similar roles and suggested that they act as nucleophiles in the enzyme-catalyzed reaction . MPA appears to inhibit completion of the IMPDH enzymatic cycle at a stage following hydride transfer and NADH release, by partially occupying the cofactor binding site. Recent elucidation of the crystal structure of hamster IMPDH in complex with IMP and MPA demonstrated this mode of inhibition and revealed a covalent adduct between Cys-331 and the C2-position of the XMP precursor reaction intermediate (Sintchak et al. 1996) . T. foetus IMPDH, however, is about 1000-fold more weakly inhibited by MPA than is the mammalian enzyme (Verham et al. 1987) . MPA inhibits mammalian enzymes with an IC 50 (K i ) in the range of 10 to 37 nM (Carr et al. 1993) and T. foetus IMPDH with an IC 50 of 7 to 9 M (Verham et al. 1987; Hedstrom and Wang 1990) . This relatively weak inhibition of T. foetus Note. T. foetus IMPDH is notably more distant from the human form of this enzyme than the other three protozoan sequences determined to date. References: T. foetus (Beck et al., 1994) , P. falciparum (Prosise, James, & Luecke, unpublished results), T. Brucei (Wilson et al., 1994) , L. donovani (Wilson et al., 1991) .
FIG. 1. Scheme for the reaction catalyzed by IMPDH:
The enzyme catalyzes the NAD-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), the committed step in guanosine monophosphate (GMP) biosynthesis.
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IMPDH by MPA, combined with conformational disorder observed at the binding sites of both the mammalian (Sintchak et al. 1996 ) and the T. foetus (Whitby et al. 1997 ) enzyme indicate that this might be an unfavorable region for structure-based inhibitor design.
We propose herein an alternative strategy to obtaining species-specific inhibitors of IMPDH. Instead of focusing on the substrate and cofactor binding regions, whose observed disorder in crystals may in fact be indicative of a mechanism relying on conformational flexibility, we propose to search for compounds that would bind tightly to a channel or groove on the surface of IMPDH which lies near the substrate binding site and includes the substrate phosphate binding pocket. We have chosen this area for the following reasons: (1) this groove is well ordered in the T. foetus x-ray structure and (2) sequence identity for residues forming this channel among different IMPDHs is lower than for the active site region, increasing chances for differential inhibition.
RESULTS AND DISCUSSION
The structure of the apo form of T. foetus IMPDH was determined by the multiple isomorphous replacement (MIR) method and refined at 2.3 Å resolution. The crystallographic R-factor for the apo model is 21.8% (R-free ‫ס‬ 26.5%) for all reflections between 8.0 and 2.3 Å resolution. Diffraction data were also collected from T. foetus IMPDH crystals that were grown or soaked in 50 mM XMP. This productcomplex crystal structure has been refined at 2.6 Å resolution to a crystallographic R-factor of 20.3% (R-free ‫ס‬ 26.4%) for all reflections between 8.0 and 2.6 Å resolution. A detailed description of the structure determination will be published elsewhere (Whitby et al. 1997) .
The crystal structure reveals a cyclically symmetric (C4) homotetramer. Each monomer buries 2224 Å 2 at the subunit interface (Whitby et al. 1997 ) which involves extensive hydrophilic interactions and size of the buried surface area suggests a stable interaction (Fig. 2a) . Each monomer is a two-domain protein of 503 amino acid residues. The principal domain includes a parallel eight-stranded ␤/␣-barrel and is formed by residues 2 to 101 and 221 to 503. The smaller domain, residues 102 to 220, is not visible in the electron density maps, presumably due to disorder. An obvious void is available in the crystal lattice to accommodate a domain of this size. This second domain is also disordered in hamster IMPDH crystals (Sintchak et al. 1996) . The function of the second domain is not known and its sequence has no apparent similarity to other proteins. Sequence alignments indicate that while GMP reductase and B. burgdorferi IMPDH show high homology with the consensus sequence of the IMPDH barrel domain, their sequences lack part or all of the disordered second domain. Recently, this 120-residue domain has been identified as a tandem repeat of the CBS motif (Bateman 1997 ) which may be involved in cytoplasmic targeting. Other disordered segments of the IMPDH structure include three flexible loops formed by residues 314 to 324 (between strand-6 and helix-6 of the barrel), 413 to 431 (following helix-8 of the barrel), and 484 to 503 (the C-terminus). The disorder of the glycine-rich loop (residues 314 to 324) that contains the active-site nucleophile, Cys-319, suggests that a high degree of flexibility may be needed for the catalytic cycle.
As is commonly seen in ␤/␣-barrel structures, the IMPDH active site is located at the C-terminal end of the ␤ strands. The structure of the barrel domain strongly resembles that of hamster IMPDH (Sintchak et al. 1996) and spinach glycolate oxidase (Schierbeek et al. 1989) . Furthermore, IMPDH bears strong sequence similarity with GMP reductase and the glycolate oxidase family of proteins, including tryptophan synthase, indole-glycerolphosphate synthase, flavocytochrome b2, lactate oxidase, and trimethylamine dehydrogenase (Bork et al. 1995) .
The active site geometry of T. foetus IMPDH is, overall, very similar to that of hamster IMPDH. Asp-358 and two water molecules that hydrogen bond to the ribose hydroxyl groups have exact counterparts in hamster IMPDH (Asp-364) (Sintchak et al. 1996) (Fig. 2b) . This aspartate is conserved in all species of IMPDH, in GMP reductase, and in several other members of the glycolate oxidase family (Bork et al. 1995) . In T. foetus IMPDH, the phosphate oxygens form one hydrogen bond each with the Tyr-405 hydroxyl, Gly-381 amide nitrogen, and an ordered water molecule. Comparable interactions are seen in the hamster enzyme. The most distinctive residue involved in substrate binding by T. foetus IMPDH is Arg-382, which is located at the N-terminal end of an ␣-helix. The charged guanidinium moiety forms a saltlink with the phosphate and its peptide amide forms a hydrogen bond with the phosphate. To date, the T. foetus enzyme represents the only IMPDH with an arginine residue at this position. Interestingly, in the apo form of T. foetus IMPDH a sulfate anion from the crystallization buffer occupies the position of the XMP phosphate, attesting to the high affinity for oxyanions of this region.
This unique arginine has led us to explore the vicinity of the substrate phosphate moiety as a target site for specific inhibitors. In addition, a deep groove or channel about 8 Å in length and 5 Å wide extends from the substrate phosphate away from the ribose moiety (Fig. 3a) . At the beginning of this channel and adjacent to O4 of the phosphate is an ordered water molecule (oxygen-oxygen distance 2.6 Å). This water molecule also accepts a hydrogen bond from the peptide amide of residue 383.
The bottom surface of the channel is mostly lined with the side chains of hydrophobic residues (Leu-380, Met-367, and phenyl moiety of Tyr-383). One side of the channel is lined with the peptide carbonyls of two consecutive residues (316/362) which could potentially interact with an inhibitor. Located at the end of the channel, about 8 Å from the phosphate, are two unpaired charged residues, Glu-364 and Arg-386, both of which-like Arg-382-are unique for the T. foetus enzyme. Their respective charged moieties are 7 Å from each other and point toward the channel (Fig. 3a) . Our current approach is to search for compounds that (a) are complementary in shape to the channel, (b) have favorable electrostatic interactions with the charged groups within this region, and (c) can be linked covalently to the substrate phosphate via an ester linkage. Such a compound, with a central phosphate group linking a substrate-like ribose moiety with a moiety that binds tightly to the channel, would be expected to act as a competitive inhibitor of the enzyme. In the most simple instance, only the phosphate moiety of the substrate would need to be. The initial stages of binding of such a hypothetical compound would require the side chain of Arg-382 to temporarily move out of the way before clamping down on the phosphate moiety.
Preliminary database searches using the program DOCK version 3.5 (Kuntz 1992; Meng et al. 1992; Meng et al. 1993; Gschwend 1995) against all phosphate-containing compounds from the Cambridge Structural Database (Allen et al. 1979) demonstrate that a large number of compounds fit in the channel region. Several of FIG. 2. (a) A ribbon drawing of the T. foetus IMPDH tetramer with product (XMP) bound. The tetramer, in which each of the four subunits is identical, is shown parallel to the 4-fold axis. The ribbon representation of one subunit is shown in lighter shades of gray and a space-filling model of XMP is shown in the active site of each monomer. The active site is formed partly by the subunit interface and contains a ␤-sheet interaction between single ␤-strands from each monomer. The N and C termini of the lightly shaded subunit are labeled. The N-terminus of one molecule is situated near one neighbor in the homotetramer while the C-terminus interacts with the other neighbor. The region between residues 101 and 222 comprises a second domain that is disordered in the crystal. (Figure produced using MOLSCRIPT (Kraulis, 1991) .) (b) A ribbon drawing of one T. foetus IMPDH monomer highlighting the active site region, viewed approximately along the axis of the ␤/␣ barrel, showing XMP bound at the C-terminal ends of the barrel ␤ strands near residues D358, R382, and Y405. Certain side chains and XMP are shown in ball-and-stick representations. Residues D364, M367, L380, Y383, and R386 define parts of the channel indicated by the shaded patch. Inhibitors are being sought that will occupy this channel and possess an oxyanion that will compete with the substrate for interaction with R382. (Figure  produced using MOLSCRIPT (Kraulis, 1991) and RASTER3D (Merritt and Murphy, 1994).) these compounds appear to make favorable electrostatic interactions with channel residues while at the same time occupying the phosphate binding site (Fig. 3b) .
Future studies will focus on identifying lead compounds which will then be tested in functional assays. In targeting our inhibitor design efforts to the channel region of T. foetus IMPDH we hope to be able to exploit the unique combination of phosphate coordination and channel electrostatics of this enzyme. (Kuntz 1992) . Part of the base of the substrate (XMP) is visible in the back. For the DOCK runs, the channel and the ribose-binding region were described by 54 spheres. Full force-field scoring was employed with estimated partial charges for the subset of the CSD database that contains at least one phosphorous atom per molecule (15,358 compounds). LUECKE, PROSISE, AND WHITBY cation. Please direct correspondence to H.L. This work is supported in part by grants from the NIH (GM56445) and the UC Irvine Cancer Center to H.L. F.G.W. is supported in part by a grant from the Lucille P. Markey Charitable Trust.
